Fennec Pharmaceuticals (NASDAQ:FENC) Upgraded by Cantor Fitzgerald to “Overweight”

Cantor Fitzgerald upgraded shares of Fennec Pharmaceuticals (NASDAQ:FENCGet Rating) from a neutral rating to an overweight rating in a report issued on Monday morning, The Fly reports.

FENC has been the topic of several other reports. Wedbush upped their target price on Fennec Pharmaceuticals from $11.00 to $19.00 in a report on Monday, September 26th. Craig Hallum reiterated a buy rating and issued a $14.00 target price on shares of Fennec Pharmaceuticals in a report on Monday, August 8th. Capital One Financial began coverage on Fennec Pharmaceuticals in a report on Wednesday, September 7th. They issued an overweight rating and a $11.00 target price on the stock. Maxim Group increased their price target on Fennec Pharmaceuticals from $10.00 to $15.00 in a report on Thursday, September 29th. Finally, HC Wainwright upped their target price on Fennec Pharmaceuticals from $14.00 to $18.00 and gave the stock a buy rating in a research report on Thursday, October 20th. Six analysts have rated the stock with a buy rating, According to MarketBeat, the company has a consensus rating of Buy and a consensus price target of $15.40.

Fennec Pharmaceuticals Stock Performance

Shares of FENC stock opened at $8.71 on Monday. The business’s 50 day simple moving average is $7.95 and its 200 day simple moving average is $6.85. Fennec Pharmaceuticals has a one year low of $3.82 and a one year high of $8.88. The stock has a market capitalization of $228.53 million and a PE ratio of -10.62. The company has a debt-to-equity ratio of 8.81, a current ratio of 10.30 and a quick ratio of 10.30.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. UBS Group AG boosted its holdings in Fennec Pharmaceuticals by 4,742.2% in the 3rd quarter. UBS Group AG now owns 3,099 shares of the company’s stock valued at $26,000 after purchasing an additional 3,035 shares during the period. Hartford Financial Management Inc. boosted its holdings in Fennec Pharmaceuticals by 14.3% in the 3rd quarter. Hartford Financial Management Inc. now owns 39,848 shares of the company’s stock valued at $323,000 after purchasing an additional 5,000 shares during the period. Jane Street Group LLC bought a new position in Fennec Pharmaceuticals in the 3rd quarter valued at $118,000. JPMorgan Chase & Co. boosted its holdings in Fennec Pharmaceuticals by 23,280.0% in the 1st quarter. JPMorgan Chase & Co. now owns 16,366 shares of the company’s stock valued at $91,000 after purchasing an additional 16,296 shares during the period. Finally, DG Capital Management LLC raised its position in shares of Fennec Pharmaceuticals by 4.4% during the 1st quarter. DG Capital Management LLC now owns 1,210,638 shares of the company’s stock valued at $6,780,000 after buying an additional 51,249 shares in the last quarter. 43.29% of the stock is owned by institutional investors.

About Fennec Pharmaceuticals

(Get Rating)

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.

Read More

The Fly logo

Analyst Recommendations for Fennec Pharmaceuticals (NASDAQ:FENC)

Receive News & Ratings for Fennec Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fennec Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.